Skip to main content
. 2020 Sep 30;12(10):935. doi: 10.3390/pharmaceutics12100935
[3H]-E1S [3H]-estrone-sulfate ammonium salt
[3H]-MTX [3H]-methotrexate
[3H]-NMQ [3H]-N-methyl quinidine
ACE angiotensin-converting-enzyme
AUC area under the curve
ANOVA analysis of variance
BSA bovine serum albumin
BCRP breast cancer resistance protein
CDCF carboxy-2′,7′-dichlorofluorescein
CES1 carboxylesterase 1
CI confidence interval
CKD chronic kidney diseases
Cmax maximum serum concentration
CMV cytomegalovirus
DMEM Dulbecco’s modified Eagle medium
E217βG estradiol 17β-d-glucuronide
EYFP enhanced yellow fluorescent protein
FBS fetal bovine serum
HBSS Hanks’ balanced salt solution
HEK293 human embryonic kidney 293
HPLC high-performance liquid chromatography
IC50 half maximal inhibitory concentration
Km substrate concentration at which half of this speed is obtained
LC-MS/MS liquid chromatography-tandem mass spectrometry
MATE1 multidrug and toxin extrusion 1
MATE2k multidrug and toxin extrusion 2k
MRP2 multidrug resistance-associated protein 2
MRP4 multidrug resistance-associated protein 4
OAT organic anion transporter
OAT1 organic anion transporter 1
OAT3 organic anion transporter 3
OATP organic anion transporting polypeptides
OCT2 organic cation transporter 2
OCTN1 organic cation/carnitine transporter 1
OCTN2 organic cation/carnitine transporter 2
PEPT1 peptide transporter 1
PEPT2 peptide transporter 2
P-gp P-glycoprotein
SEM standard error of the mean
URAT1 urate transporter 1
Vmax maximum transport velocity